Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 24, 2011

View Archived Issues

Ibuprofen derivative mitigates effects of murine muscular dystrophy

New phosphodiesterase 3/4 inhibitor shows anti-inflammatory and bronchodilatory effects

Abbott reviews business highlights of third quarter 2011

Genfit's GFT-505 increases sensitivity to insulin in target organs

Cytonet expands SELICA III study to Canada

Study suggests montelukast improves pediatric atopic dermatitis

Pazopanib activity reported in soft tissue sarcoma and urothelial cancer

Phase II trials assess belinostat in bladder cancer and hepatocellular carcinoma

Korean research team presents novel angiogenesis inducers

New antisense oligonucleotides synthesized at Mirrx Therapeutics

Matrix Pharma claims novel thrombin inhibitors

Okayama University discloses new COX-1 inhibitors

Novel antivirals prepared at Vertex

Halozyme reports phase II data on ultrafast insulin analogue formulations

AMAG Pharmaceuticals terminates merger agreement

Dynavax and GSK add new target in Toll-like receptor inhibitor program

Intercell reports first-in-human data on Clostridium difficile vaccine

FDA to review linaclotide NDA

Daiichi Sankyo and AstraZeneca seek approval for new Nexium indication in Japan

CHMP clarifies opinion on pioglitazone and the risk of bladder cancer

Progenra and Tokyo Medical University begin rheumatoid arthritis collaboration

FDA issues update on drug interactions with linezolid

Silence Therapeutics and Mirna Therapeutics enter microRNA collaboration

First-in-human AVI-6003 trial advances

FDA approves label update for Prezista